Sanofi deepens cancer treatment research deal with Warp Drive

PARIS (Reuters) – Sanofi and biotech company Warp Drive Bio said on Monday they had deepened their existing partnership in cancer drug research with $750 million in new funding from the French drugmaker.

Under the deal, Warp Drive will lead joint research on new cancer drugs, the companies said in a joint statement. Sanofi will hold exclusive global licenses to develop and commercialize the treatments discovered by the program.

Sanofi has been a major backer of privately held Warp Drive since its creation in 2012.

Earlier on Monday, Sanofi also announced a research collaboration with Innate Pharma in immuno-oncology.

(Reporting by Laurence Frost; Editing by James Regan)

• Disease Medical Conditions
• Health
• Warp Drive
• Sanofi